209 related articles for article (PubMed ID: 1660525)
1. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity.
Peppel K; Crawford D; Beutler B
J Exp Med; 1991 Dec; 174(6):1483-9. PubMed ID: 1660525
[TBL] [Abstract][Full Text] [Related]
2. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
[TBL] [Abstract][Full Text] [Related]
3. Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity.
Loetscher H; Gentz R; Zulauf M; Lustig A; Tabuchi H; Schlaeger EJ; Brockhaus M; Gallati H; Manneberg M; Lesslauer W
J Biol Chem; 1991 Sep; 266(27):18324-9. PubMed ID: 1655744
[TBL] [Abstract][Full Text] [Related]
4. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins.
Scallon BJ; Trinh H; Nedelman M; Brennan FM; Feldmann M; Ghrayeb J
Cytokine; 1995 Nov; 7(8):759-70. PubMed ID: 8664442
[TBL] [Abstract][Full Text] [Related]
5. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.
Wright A; Morrison SL
J Exp Med; 1994 Sep; 180(3):1087-96. PubMed ID: 8064227
[TBL] [Abstract][Full Text] [Related]
6. An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.
Berger V; Richter F; Zettlitz K; Unverdorben F; Scheurich P; Herrmann A; Pfizenmaier K; Kontermann RE
Protein Eng Des Sel; 2013 Oct; 26(10):581-7. PubMed ID: 24006371
[TBL] [Abstract][Full Text] [Related]
7. Expression of a TNF inhibitor in transgenic mice.
Peppel K; Poltorak A; Melhado I; Jirik F; Beutler B
J Immunol; 1993 Nov; 151(10):5699-703. PubMed ID: 7693816
[TBL] [Abstract][Full Text] [Related]
8. Construction and expression of a mouse-human chimeric antibody against human tumor necrosis factor-alpha.
Nagahira K; Fukuda Y; Nasu T; Kawashima H; Noguchi C; Kurihara T; Oikawa S; Nakanishi T
Immunol Lett; 1998 Dec; 64(2-3):139-44. PubMed ID: 9870665
[TBL] [Abstract][Full Text] [Related]
9. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.
Ashkenazi A; Marsters SA; Capon DJ; Chamow SM; Figari IS; Pennica D; Goeddel DV; Palladino MA; Smith DH
Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10535-9. PubMed ID: 1660140
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody.
Haak-Frendscho M; Marsters SA; Mordenti J; Brady S; Gillett NA; Chen SA; Ashkenazi A
J Immunol; 1994 Feb; 152(3):1347-53. PubMed ID: 8301136
[TBL] [Abstract][Full Text] [Related]
11. Soluble tumor necrosis factor receptor: inhibition of human immunodeficiency virus activation.
Howard OM; Clouse KA; Smith C; Goodwin RG; Farrar WL
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2335-9. PubMed ID: 7681592
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor.
Zhou QH; Sumbria R; Hui EK; Lu JZ; Boado RJ; Pardridge WM
J Pharmacol Exp Ther; 2011 Nov; 339(2):618-23. PubMed ID: 21831964
[TBL] [Abstract][Full Text] [Related]
13. Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein.
Himmler A; Maurer-Fogy I; Krönke M; Scheurich P; Pfizenmaier K; Lantz M; Olsson I; Hauptmann R; Stratowa C; Adolf GR
DNA Cell Biol; 1990 Dec; 9(10):705-15. PubMed ID: 1702293
[TBL] [Abstract][Full Text] [Related]
14. Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.
Browning JL; Dougas I; Ngam-ek A; Bourdon PR; Ehrenfels BN; Miatkowski K; Zafari M; Yampaglia AM; Lawton P; Meier W
J Immunol; 1995 Jan; 154(1):33-46. PubMed ID: 7995952
[TBL] [Abstract][Full Text] [Related]
15. Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding.
Marsters SA; Frutkin AD; Simpson NJ; Fendly BM; Ashkenazi A
J Biol Chem; 1992 Mar; 267(9):5747-50. PubMed ID: 1313418
[TBL] [Abstract][Full Text] [Related]
16. Production of lymphotoxin (LT alpha) and a soluble dimeric form of its receptor using the baculovirus expression system.
Crowe PD; VanArsdale TL; Walter BN; Dahms KM; Ware CF
J Immunol Methods; 1994 Jan; 168(1):79-89. PubMed ID: 8288897
[TBL] [Abstract][Full Text] [Related]
17. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
Qin W; Feng J; Li Y; Lin Z; Shen B
Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
[TBL] [Abstract][Full Text] [Related]
18. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
[TBL] [Abstract][Full Text] [Related]
19. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor.
Kohno T; Brewer MT; Baker SL; Schwartz PE; King MW; Hale KK; Squires CH; Thompson RC; Vannice JL
Proc Natl Acad Sci U S A; 1990 Nov; 87(21):8331-5. PubMed ID: 2172983
[TBL] [Abstract][Full Text] [Related]
20. Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines.
Estrov Z; Kurzrock R; Pocsik E; Pathak S; Kantarjian HM; Zipf TF; Harris D; Talpaz M; Aggarwal BB
J Exp Med; 1993 Mar; 177(3):763-74. PubMed ID: 8382256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
